Journals / Retina-Vitreus / 2005 / Cilt: 13 - Sayı: 1

Makula dejeneransı tedavisinde yeni bir dönem başlıyor

Pages
1–7
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

However, the benefit and cost of these agents and other alternative treatments should be well studied and assessed for the social, demographic and economical status of the patient population in the countries these are to be adopted.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Current standard management of choroidal neovascular membranes developing secondary to agerelated macular degeneration consists of thermal laser photocoagulation and photodynamic therapy based on the lesion location, size and fluorescein angiographic characteristics.
📊
Key Findings & Data:In the next several years, numerous antiangiogenic substances (including Pegaptanib, Ranibizumab, and Anecortave Acetate) will be available and possibly superior to the current alternatives for use as monotherapy or combination therapy as the standard care for subfoveal CNVM.
💡
Conclusion & Impact:However, the benefit and cost of these agents and other alternative treatments should be well studied and assessed for the social, demographic and economical status of the patient population in the countries these are to be adopted.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Antikorlar · monoklonal · Maküler dejenerasyon

Abstract

Current standard management of choroidal neovascular membranes developing secondary to agerelated macular degeneration consists of thermal laser photocoagulation and photodynamic therapy based on the lesion location, size and fluorescein angiographic characteristics. In the next several years, numerous antiangiogenic substances (including Pegaptanib, Ranibizumab, and Anecortave Acetate) will be available and possibly superior to the current alternatives for use as monotherapy or combination therapy as the standard care for subfoveal CNVM. However, the benefit and cost of these agents and other alternative treatments should be well studied and assessed for the social, demographic and economical status of the patient population in the countries these are to be adopted.

Özet

Yaşa bağlı makula dejeneransına sekonder olarak gelişen koroidal neovasküler membranların mevcut standart tedavisi; lezyonun yerleşimi, büyüklüğü ve floresan anjiografi bulgularına dayanarak termal laser fotokoagulasyon veya fotodinamik tedavi uygulanmasıdır. Önümüzdeki birkaç yılda, subfoveal koroidal neovasküler membranların standart tedavisinde monoterapi veya kombinasyon terapisi olarak kullanılabilecek ve mevcut alternatiflerden muhtemelen daha üstün olabilecek Pegaptanib, Ranibizumab ve Anecortave Acetate gibi pek çok anti-anjiogenetik madde piyasaya sürülecektir. Buna rağmen bu ajanların ve diğer tedavilerin maliyetleri ve faydaları kullanılacağı ülkenin sosyal, ekonomik ve demografik durumu göz önüne alınarak iyice etüt edilmelidir.

🔖

Cite This Article

YALÇINBAYIR, Ö., FİROZVİ, A., AKDUMAN, L. (2005). Makula dejeneransı tedavisinde yeni bir dönem başlıyor. Retina-Vitreus, Cilt: 13 - Sayı: 1, 1–7. https://ajindex.com/articles/307958

References (11)

  1. Klein R, Klein BE, Jensen SC et al.: The five-year incidence and progression of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology 1997;104:7-21
  2. Leibowitz HM, Krueger DE, Maunder LR et al.: The Framingham Eye Study monograph: an ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973-1975. Surv Ophthalmol. 1980;24:335-610
  3. Young RW.: Pathophysiology of age-related macular degeneration. Surv Ophthalmol. 1987;31:291-306
  4. Chamberlin JA, Bressler NM, Bressler SB, et al.: The use of fundus photographs and fluorescein angiograms in the identification and treatment of choroidal neovascularization in the Macular Pho-tocoagulation Study Group. Ophthalmology 1989;96:1526-1534
  5. Martidis A, Tennant MTS.: Age-related Macular Degeneration.In: Yanoff M, Duker JS editors. Ophthalmology, 2nd Edition. Mosby, St.Louis. 2004. Chapter 125; 925-933
  6. Spaide RE: Choroidal neovascularization. In: Yanoff M, Duker JS editors. Ophthalmology, 2nd Edition. Mosby, St.Louis. 2004. Chapter 124; 919-924
  7. Macular Photocoagulation Study Group.: Krypton laser photocoagulation for neovascular lesions of age-related macular degeneration. Results of a randomized trial. Arch Ophthalmol 1990,108:816-824 8. Macular Photocoagulation Study Group.: Argon laser pho-tocoagulation for neovascular retinopathy after five years. Results from randomized trials. Arch Ophthalmol 1991; 109:1109-1114
  8. Macular Photocoagulation Study Group.: Laser photocoagulation for juxtafoveal choroidal neovascularization. Five-year results from randomized clinical trial. Arch Ophthalmol 1994;112:500-509
  9. Macular Photocoagulation Study Group.: Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized trial. Arch Ophthalmol 1991,-109:1219-1230 11. Treatment of age-related macular degeneration with photodynamic therapy (TAP) study group.: Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin; one-year results of 2 randomized clinical trial- TAP report 1. Arch Ophthalmol. 1999;117:1329-1345
  10. Bressler NM.: Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with Verteporfin: two-year results of 2 randomized clinical trials- TAP report 2. Arch Ophthalmol 2001;119:198-207
  11. Vertoporfin in Photodynamic T